Goodwin (JD Supra Japan)
7 results for Goodwin (JD Supra Japan)
-
Alvotech and DKSH Extend Partnership in Asia
Alvotech and DKSH recently announced an expansion of their strategic partnership to commercialize six new biosimilar candidates for the Asian markets. The press release does not name the biosimilar candidates, but states that they “address[] multiple therapeutic areas.”
-
Lupin and Nichi-Iko Collaborate to Market Etanercept Biosimilar in Japan
As we reported last month, YL Biologics (a joint venture between Lupin’s subsidiary Kyowa and Yoshindo) recently submitted a New Drug Application (NDA) for Marketing Authorization of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for YLB113, a proposed biosimilar of Enbrel® (etanercept). Yesterday, Lupin and Nichi-Iko Pharmaceutical announced that they have entered into an agreement
-
Lupin Announces Positive Results For Etanercept Biosimilar
On February 7, 2018, Lupin announced positive results from a Phase III clinical trial for its etanercept biosimilar candidate, YB113. YB113 is being developed by YL Biologics, a joint venture of Lupin and Yoshido, a Japanese pharmaceutical company.
-
First Etanercept Biosimilar to Receive Sales Approval in Japan
Last Friday, Japanese company Mochida Pharmaceutical with Korean company LG Chem announced that it has received sales approval from the Japanese Ministry of Health, Labour and Welfare on its etanercept biosimilar (marketed by Amgen as ENBREL®) for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis. LG Chem has a sales contract with local company Mochida Pharmaceutical which...
-
Discontinuation of Etanercept Biosimilar in Japan
On July 5, 2017, Daiichi Sankyo Company announced that it has decided to discontinue the development of CHS-0214, an investigational biosimilar to Amgen’s Enbrel® (etanercept), in Japan. Daiichi had been co-developing CHS-0214 with Coherus BioSciences, who still holds rights to CHS-0214 outside of Japan.
-
Deal Watch: Teva Signs Agreement with Otsuka for Exclusive Rights to Migraine Antibody in Japan
Otsuka announced today that it has agreed to pay Teva $50 million and later milestone payments for the exclusive rights to develop and commercialize Fremanezumab in Japan. Fremanezumab, which targets the calcitonin gene-related peptide, is a monthly subcutaneous injection that Teva has been developing globally for the treatment of migrane, including chronic and episodic migraine, and chronic and...
-
Celltrion and Nippon Kayaku Strike Deal for Rituxan Biosimilar
On April 27, 2017, The Korea Herald and The Investor reported that Celltrion and Nippon Kayaku entered into an agreement under which Nippon Kayaku will sell Truxima, Celltrion’s biosimilar of Rituxan, in Japan. According to the articles, Nippon Kayaku has exclusive rights to sell Celltrion’s Truxima, Remsima and Herzuma, and the parties will conduct clinical trials of Rituxan in Japan prior to...